The MS pill saw rapid uptake in the US last year, but its overseas launch won’t be as quick, CEO George Scangos conceded this week at an analyst conference.
The year’s most popular stories
December 31, 2013
4:13 pm
Our year-end list captures the 10 that sparked heaviest interest.
Most patients would advise today’s FDA Lemtrada panel to allow doctors to gauge the drug’s risk-benefit profile, although there was strong sentiment on either side of the issue.